Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary

Dewailly, Didier; Robin, Geoffroy; Peigné, Maëliss; Decanter, Christine; Pigny, Pascal; Catteau-Jonard, Sophie

doi:10.1093/humupd/dmw027

Cited by 393 publications

(264 citation statements)

References 152 publications

Supporting

Mentioning

243

Contrasting

Unclassified

Order By: Relevance

“…The message provided by in vitro studies is that highly steroidogenic gonadotropins, i.e., FSH and hCG, mediate apoptotic stimuli in granulosa cells via cAMP/PKA-pathway (2, 3, 29–31). In the ovarian setting of a multi-follicular maturation as in COS, stimulation is a potent signal for early tertiary follicle recruitment (34) and triggering steroidogenesis, results in estrogen over-production which, in turn, induces more pronounced multi-follicular survival and maturation (35) than that inducible by LH treatment.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era: A Meta-analysis

et al. 2017

View full text Add to dashboard Cite

SettingLuteinizing hormone (LH) and human chorionic gonadotropin (hCG) act on the same receptor, activating different signal transduction pathways. The role of LH or hCG addition to follicle-stimulating hormone (FSH) as well as menopausal gonadotropins (human menopausal gonadotropin; hMG) in controlled ovarian stimulation (COS) is debated.ObjectiveTo compare FSH + LH, or FSH + hCG or hMG vs. FSH alone on COS outcomes.DesignA meta-analysis according to PRISMA statement and Cochrane Collaboration was performed, including prospective, controlled clinical trials published until July 2016, enrolling women treated with FSH alone or combined with other gonadotropins. Trials enrolling women with polycystic ovarian syndrome were excluded (PROSPERO registration no. CRD42016048404).ResultsConsidering 70 studies, the administration of FSH alone resulted in higher number of oocytes retrieved than FSH + LH or hMG. The MII oocytes number did not change when FSH alone was compared to FSH + LH, FSH + hCG, or hMG. Embryo number and implantation rate were higher when hMG was used instead of FSH alone. Pregnancy rate was significantly higher in FSH + LH-treated group vs. others. Only 12 studies reported live birth rate, not providing protocol-dependent differences. Patients’ stratification by GnRH agonist/antagonist identified patient subgroups benefiting from specific drug combinations.ConclusionIn COS, FSH alone results in higher oocyte number. HMG improves the collection of mature oocytes, embryos, and increases implantation rate. On the other hand, LH addition leads to higher pregnancy rate. This study supports the concept of a different clinical action of gonadotropins in COS, reflecting previous in vitro data.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era: A Meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…anovulation, hyperandrogenism and ultrasonographic features. 14 It is thought that androgens may play a key role in increasing the number of follicles 15 and induce follicular development. 16 Vendola et al 16 found a higher number of developing follicles with larger granulosa and theca cells in adult female Rhesus monkeys that received testosterone and dihydrotestosterone for treatment compared with placebo.…”

Section: Discussionmentioning

confidence: 99%

Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes

Eftekhar

Mirhashemi

Tabibnejad

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To explore assisted reproductive outcomes among women with different polycystic ovary syndrome (PCOS) phenotypes. Methods A retrospective cohort study included women with PCOS who were treated at Yazd Research and Clinical Center for Infertility, Yazd, Iran, using the GnRH antagonist protocol between April 1, 2015, and August 31, 2017. Clinical pregnancy was the primary outcome, and chemical pregnancy, implantation rate, fertilization rate, and spontaneous abortion rate, were the secondary outcomes that were evaluated among four defined phenotypes of women with PCOS. Results Significant differences were observed between the phenotypes for the levels of luteinizing hormone, anti‐Müllerian hormone, fasting blood sugar, and total testosterone concentration; similarly, the percentage of women with luteinizing hormone/follicle stimulating hormone ratio of at least 2.5 differed between PCOS phenotypes (all P<0.001). There were also significant differences in estradiol level (P<0.001) and the number of matured follicles (P=0.002) between different phenotypes. No significant differences were observed in the fertilization and implantation rates, as well as chemical and clinical pregnancy rates (all P>0.05). Conclusion No significant differences were observed in assisted reproductive technique outcome among women with different phenotypes of PCOS undergoing frozen‐thawed embryo transfer.

show abstract

“…This is because the estradiol level in follicular fluid from small antral follicles seems to be connected with AMH. It is likely that FSH induces a down regulation of AMH expression through rising follicle estradiol levels 24,25 There are at a minimum three biological characteristics that AMH displays which are clinically worthy and not in alignment with the conventional hormonal predictors of ovarian reserve. First, AMH is exhibited in granulosa cells of small growing follicles 8,9 Second, follicles that grow past the early antral follicle stage begin to lose their ability to express AMH, largely avoiding AMH measurements from bias that are linked to early follicular development, which is especially common in ovarian-aged women.…”

Section: Introductionmentioning

confidence: 99%

Relationship Between Serum Antimullerian Hormone, Follicular Stimulating Hormone, and Luteal Hormone Levels With Ovarian Follicular Status on Day Three of Menstrual Cycle

Alamieer¹,

Shubber²,

Azeez³

2019

Int. Res. J. Pharm.

View full text Add to dashboard Cite

Background: An assessment of the follicular reserve is essential to define the follicular status of the ovary. Various methods have been utilized to measure how many follicles are in the ovaries, including FSH, LH, AMH and AFC by Transvaginal ultrasound. This study aims to identify the correlation that exists between the different ovarian function markers. Objectives: To compare the relationship between serum AMH, FSH, and LH levels with AFC on day 3 of a menstrual cycle. Patients and methods: 100 infertile women in the department of obstetrics and gynecology at Al-Emameen Al-Khadimen Medical City were studied on day 3 of their menstrual cycle from April 1, 2014 to April 1, 2015. Measurements were taken for serum AMH, FSH, LH levels and AFC. Results: Median (range) serum levels of AMH, FSH, and LH were 2.45 ng/ml (0.24-6.5), 5.6 mIU/ml (2.1-19.3), 2.3 mIU/ml (1.1-10.0) respectively, and AFC was 15 (1-35). Serum AMH levels correlated more strongly with follicular count (r = 0.965 p ˂ 0.001) than levels of FSH (r =-0.446 p ˂ 0.001) and LH (r = 0.049 p = 0.625). Conclusion: Serum AMH levels showed a stronger correlation with the AFC on cycle day 3. This is an indication that AMH may demonstrate ovarian follicular status better than the hormone markers usually used.

show abstract

Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary

Cited by 393 publications

References 152 publications

Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era: A Meta-analysis

Efficacy of Follicle-Stimulating Hormone (FSH) Alone, FSH + Luteinizing Hormone, Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era: A Meta-analysis

Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes

Relationship Between Serum Antimullerian Hormone, Follicular Stimulating Hormone, and Luteal Hormone Levels With Ovarian Follicular Status on Day Three of Menstrual Cycle

Contact Info

Product

Resources

About